Abortion Pill Case Heads to Supreme Court: Why the Facts the ACLJ Presented Matter More Than Ever
We’ve previously told you how the ACLJ is exposing abortion pill myths in federal court. Now with a major ruling from the U.S. Court of Appeals for the Fifth Circuit and a rapid response from the Supreme Court of the United States, the stakes have only grown higher.
The Fifth Circuit restored critical safeguards on abortion drugs – requiring in-person dispensing and rejecting the FDA’s sweeping deregulation of these powerful medications. That decision directly addressed concerns the ACLJ has been raising: that the federal government cannot simply strip away safety protocols without consequence.
FDA’s 2023 mifepristone label reports that 2.9 to 4.6 percent of women prescribed mifepristone in-person will require emergency care. (FDA’s “own documents . . . prove that emergency room care is statistically certain in hundreds of thousands of cases”). Remotely dispensing the drug will only exacerbate those risks, as the district court found. (“[T]he literature suggests there may be more frequent ED/urgent care visits related to the use of mifepristone when dispensed by mail . . . .”).
But within days, the Supreme Court issued a temporary stay, allowing mail-order abortion drugs to continue – at least until May 11. That temporary pause is in place while Louisiana responds to the abortion pill manufacturers’ appeal to the Supreme Court to undo the lower court’s order. It does not resolve the case. It simply underscores how serious the issues are. And those issues are exactly what the ACLJ has placed front and center.
One of the central claims pushed by abortion advocates and manufacturers is that chemical abortion is routine and risk-free. Our brief directly confronts that narrative.
Abortion pills are not designed to treat an illness or improve health. They are designed to induce a serious medical event – pregnancy loss. As the ACLJ has explained, calling that outcome a low-risk side effect is fundamentally misleading.
And the risks are not hypothetical. The drug regimen can involve significant complications, including hemorrhage and infection – often occurring outside of a clinical setting, with no physician present. That reality becomes even more concerning when the safeguards requiring in-person evaluation are removed.
Another key issue we raised – and one the courts are now being forced to confront – is the breakdown of informed consent.
Basic medical ethics require that patients understand the risks, alternatives, and consequences of a treatment. But that standard becomes nearly impossible to meet in a mail-order abortion regime.
Without an in-person exam, providers cannot reliably confirm gestational age, rule out ectopic pregnancy, or ensure that the patient is not being coerced.
As other filings in this litigation have emphasized, informed consent requires “adequate disclosure” and freedom from coercion – conditions that are undermined under the current FDA protocol.
That is not expanded care. That is diminished medical protection.
Perhaps one of the most overlooked – and most disturbing – issues highlighted in our brief is how abortion pills can be used by third parties to harm women. Because these drugs can be obtained without in-person oversight, they are uniquely susceptible to misuse.
The ACLJ has documented how traffickers, abusers, and predators can use abortion pills to conceal abuse or force unwanted abortions – without ever bringing a woman into a clinical setting. Other evidence in the record reinforces this concern, showing that abortion coercion is a real and documented problem, often linked to intimate partner violence.
When you remove safeguards, you don’t just increase access – you increase vulnerability.
At its core, this case is not just about abortion. It is about whether federal agencies can bypass longstanding safeguards and effectively nullify state law. The Fifth Circuit recognized that the FDA’s actions – particularly its removal of in-person requirements and expansion of mail distribution – raise serious legal questions.
That is why the ACLJ is preparing to file an amicus brief this week with the Supreme Court of the United States, urging the Court to keep the Fifth Circuit’s order in place.
We will be asking the Court to restore the safeguards that protect women – not just in theory, but in practice.
This case is about more than access. It is about truth. It is about whether the law will recognize the real-world consequences of these drugs – and whether basic medical standards still matter.
And the ACLJ will continue to ensure that the Court hears what the abortion industry would rather ignore. Stand with us as we fight to protect women and preborn children. Be their voice – sign the petition: Defeat the Abortion Pill at the Supreme Court.